Schedule 13G ownership disclosure
CRINETICS PHARMACEUTICALS INC
Common Stock · CUSIP: 22663K107
Event date: 2024-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Wellington Management Group LLP
Shares: 6,950,567.00 · Class: 7.5%
- Wellington Group Holdings LLP
Shares: 6,950,567.00 · Class: 7.5%
- Wellington Investment Advisors Holdings LLP
Shares: 6,950,567.00 · Class: 7.5%
- Wellington Management Company LLP
Shares: 6,950,567.00 · Class: 7.1%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000902219-25-000051
- Form type
- SCHEDULE 13G/A
- Filer
- Crinetics Pharmaceuticals, Inc.
- CIK
- CIK 1658247
- Filed
- Feb 10, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership